Banner

Pulmonary Arterial Hypertension Global Market Report 2023 – By Drug Class (Endothelin Receptor Antagonists (ERAs), PDE 5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational), By Distribution channel (Retail, Online) – Market Size, Trends, And Global Forecast 2023-2032

Starting Price : $5000.00 | Pages : 200 | Published : January 2023 | SKU CODE : h1619 | Delivery Time: 2-3 business days | Format :


Pulmonary arterial hypertension refers to a form of excessive blood pressure that harms the right side of the heart and the arteries in the lungs. The lungs' artery walls become constricted and rigid due to this long-lasting, incurable condition. The pulmonary arterial hypertension drugs relax the muscles in the walls of the blood vessels, increase the blood flow through the lungs, or reverse the effect of the substance in the walls of blood vessels that causes them to narrow.

The main types of pulmonary arterial hypertension drug classes are endothelin receptor antagonists (ERAS), PDE-5 inhibitors, prostacyclin and prostacyclin analogs, and SGC stimulators. Endothelin receptor antagonists (ERAs) are a form of targeted medication that is used to treat pulmonary hypertension in patients (PH). Targeted medicines can help to reduce the course of PH and potentially reverse some of the heart and lung damage. The drugs are administered through oral, intravenous/subcutaneous, and inhalational modes and distributed through retail and online channels.

The pulmonary arterial hypertension market research report is one of a series of new reports from The Business Research Company that provides pulmonary arterial hypertension market statistics, including pulmonary arterial hypertension industry global market size, regional shares, competitors with a pulmonary arterial hypertension market share, detailed pulmonary arterial hypertension market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary arterial hypertension industry. This pulmonary arterial hypertension market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The global pulmonary arterial hypertension market size grew from $7.05 billion in 2022 to $7.63 billion in 2023 at a compound annual growth rate (CAGR) of 8.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pulmonary arterial hypertension market size is expected to grow to $10.47 billion in 2027 at a CAGR of 8.2%.

The increasing prevalence of pulmonary arterial hypertension (PAH) disease is contributing to the growth of the pulmonary arterial hypertension market. The increasing prevalence of PAH diseases and the related hospitalisation of patients for treatment is expected to boost the demand for relevant drugs during the forecast period. According to a study published by the National Organization for Rare Disorders, Inc., new cases of PAH are estimated to occur in one to two individuals per million each year in the USA, which equates to 500–1000 new cases each year, and Europe is expected to have similar incidence rates.

Technological advancements are key trends gaining popularity in the pulmonary arterial hypertension market. The companies operating in the pulmonary arterial hypertension drug sector are focusing on developing new medicines to improve and cure these diseases. For instance, in April 2021, United Therapeutics Corporation, a US-based biotechnology company, launched Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease. Tyvaso is an inhalation solution that helps patients enhance their exercise abilities, reduce breathing difficulties, have a low tolerance for exertion, and have a higher mortality rate.

In September 2021, Merck Group, a German-based multinational science and technology company that specialises in healthcare and life sciences solutions, acquired Acceleron Pharma for $11 billion. Through this acquisition, Merck will obtain ownership of Acceleron's portfolio of rare illness therapies, including sotatercept, a Phase III pulmonary arterial hypertension (PAH) medication, and also puts the company at the forefront of rare disease-focused companies. Acceleron Pharma is a US-based company committed to the research, development, and commercialization of therapies for the treatment of critical and uncommon conditions such as pulmonary arterial hypertension.

Major players in the pulmonary arterial hypertension market are United Therapeutics Corporation, Bayer AG, Gilead Sciences Inc., Johnson & Johnson, GlaxoSmithKline, Pfizer Inc., Sandoz AG, Lupin Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Eli Lilly and Company, Actelion Pharmaceuticals US Inc., Natco Pharma Ltd., Zydus Pharmaceutical USA, and Liquidia Technologies Inc.

North America was the largest region in the pulmonary arterial hypertension market in 2022. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the pulmonary arterial hypertension market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA.

The pulmonary arterial hypertension market includes revenues earned by entities by idiopathic, heritable, and drug and toxin-induced. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The global pulmonary arterial hypertension market is segmented -

1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators

2) By Route of Administration: Oral, Intravenous/ subcutaneous, Inhalational

3) By Distribution channel: Retail, Online

    Table Of Contents

    1. Executive Summary

    2. Pulmonary Arterial Hypertension Market Characteristics

    3. Pulmonary Arterial Hypertension Market Trends And Strategies

    4. Pulmonary Arterial Hypertension Market – Macro Economic Scenario

    4.1 COVID-19 Impact On Pulmonary Arterial Hypertension Market

    4.2 Ukraine-Russia War Impact On Pulmonary Arterial Hypertension Market

    4.3 Impact Of High Inflation On Pulmonary Arterial Hypertension Market

    5. Pulmonary Arterial Hypertension Market Size And Growth

    5.1. Global Pulmonary Arterial Hypertension Historic Market, 2017-2022, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Pulmonary Arterial Hypertension Forecast Market, 2022-2027F, 2032F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Pulmonary Arterial Hypertension Market Segmentation

    6.1. Global Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Endothelin Receptor Antagonists (ERAs)

    PDE-5 Inhibitors

    Prostacyclin and Prostacyclin Analogs

    SGC Stimulators

    6.2. Global Pulmonary Arterial Hypertension Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Oral

    Intravenous/ subcutaneous

    Inhalational

    6.3. Global Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Retail

    Online

    7. Pulmonary Arterial Hypertension Market Regional And Country Analysis

    7.1. Global Pulmonary Arterial Hypertension Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    7.2. Global Pulmonary Arterial Hypertension Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8. Asia-Pacific Pulmonary Arterial Hypertension Market

    8.1. Asia-Pacific Pulmonary Arterial Hypertension Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.3. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    9. China Pulmonary Arterial Hypertension Market

    9.1. China Pulmonary Arterial Hypertension Market Overview

    9.2. China Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.3. China Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    10. India Pulmonary Arterial Hypertension Market

    10.1. India Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.2. India Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11. Japan Pulmonary Arterial Hypertension Market

    11.1. Japan Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.2. Japan Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12. Australia Pulmonary Arterial Hypertension Market

    12.1. Australia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.2. Australia Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13. Indonesia Pulmonary Arterial Hypertension Market

    13.1. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.2. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14. South Korea Pulmonary Arterial Hypertension Market

    14.1. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.2. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15. Western Europe Pulmonary Arterial Hypertension Market

    15.1. Western Europe Pulmonary Arterial Hypertension Market Overview

    15.2. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.3. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16. UK Pulmonary Arterial Hypertension Market

    16.1. UK Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.2. UK Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17. Germany Pulmonary Arterial Hypertension Market

    17.1. Germany Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.2. Germany Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18. France Pulmonary Arterial Hypertension Market

    18.4. France Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.5. France Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19. Eastern Europe Pulmonary Arterial Hypertension Market

    19.1. Eastern Europe Pulmonary Arterial Hypertension Market Overview

    19.2. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.3. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20. Russia Pulmonary Arterial Hypertension Market

    20.1. Russia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.2. Russia Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21. North America Pulmonary Arterial Hypertension Market

    21.1. North America Pulmonary Arterial Hypertension Market Overview

    21.2. North America Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.3. North America Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22. USA Pulmonary Arterial Hypertension Market

    22.1. USA Pulmonary Arterial Hypertension Market Overview

    22.2. USA Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.3. USA Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23. South America Pulmonary Arterial Hypertension Market

    23.1. South America Pulmonary Arterial Hypertension Market Overview

    23.2. South America Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.3. South America Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24. Brazil Pulmonary Arterial Hypertension Market

    24.1. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.2. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25. Middle East Pulmonary Arterial Hypertension Market

    25.1. Middle East Pulmonary Arterial Hypertension Market Overview

    25.2. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.3. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26. Africa Pulmonary Arterial Hypertension Market

    26.1. Africa Pulmonary Arterial Hypertension Market Overview

    26.2. Africa Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.3. Africa Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27. Pulmonary Arterial Hypertension Market Competitive Landscape And Company Profiles

    27.1. Pulmonary Arterial Hypertension Market Competitive Landscape

    27.2. Pulmonary Arterial Hypertension Market Company Profiles

    27.2.1. United Therapeutics Corporation

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Bayer AG

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Gilead Sciences Inc.

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Johnson & Johnson

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. GlaxoSmithKline

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Key Mergers And Acquisitions In The Pulmonary Arterial Hypertension Market

    29. Pulmonary Arterial Hypertension Market Future Outlook and Potential Analysis

    30. Appendix

    30.1. Abbreviations

    30.2. Currencies

    30.3. Historic And Forecast Inflation Rates

    30.4. Research Inquiries

    30.5. The Business Research Company

    30.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3: Global Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4: Global Pulmonary Arterial Hypertension Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5: Global Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6: Global Pulmonary Arterial Hypertension Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7: Global Pulmonary Arterial Hypertension Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8: Asia-Pacific, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9: Asia-Pacific, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10: China, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11: China, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12: India, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13: India, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14: Japan, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15: Japan, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16: Australia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17: Australia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18: Indonesia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19: Indonesia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20: South Korea, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21: South Korea, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22: Western Europe, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23: Western Europe, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24: UK, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25: UK, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26: Germany, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27: Germany, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 28: France, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 29: France, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 30: Eastern Europe, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 31: Eastern Europe, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 32: Russia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 33: Russia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 34: North America, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 35: North America, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 36: USA, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 37: USA, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 38: South America, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 39: South America, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 40: Brazil, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 41: Brazil, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 42: Middle East, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 43: Middle East, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 44: Africa, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 45: Africa, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 46: United Therapeutics Corporation Financial Performance
  • Table 47: Bayer AG Financial Performance
  • Table 48: Gilead Sciences Inc., Financial Performance
  • Table 49: Johnson & Johnson Financial Performance
  • Table 50: GlaxoSmithKline Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3: Global Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4: Global Pulmonary Arterial Hypertension Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5: Global Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6: Global Pulmonary Arterial Hypertension Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7: Global Pulmonary Arterial Hypertension Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8: Asia-Pacific, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9: Asia-Pacific, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10: China, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11: China, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12: India, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13: India, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14: Japan, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15: Japan, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16: Australia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17: Australia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18: Indonesia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19: Indonesia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20: South Korea, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21: South Korea, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22: Western Europe, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23: Western Europe, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24: UK, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25: UK, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26: Germany, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27: Germany, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 28: France, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 29: France, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 30: Eastern Europe, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 31: Eastern Europe, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 32: Russia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 33: Russia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 34: North America, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 35: North America, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 36: USA, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 37: USA, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 38: South America, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 39: South America, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 40: Brazil, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 41: Brazil, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 42: Middle East, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 43: Middle East, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 44: Africa, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 45: Africa, Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 46: United Therapeutics Corporation Financial Performance
  • Figure 47: Bayer AG Financial Performance
  • Figure 48: Gilead Sciences Inc., Financial Performance
  • Figure 49: Johnson & Johnson Financial Performance
  • Figure 50: GlaxoSmithKline Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report